Literature DB >> 6208604

Plasma proteinase inhibitors.

J L Bodmer, H P Schnebli.   

Abstract

Plasma proteinase inhibitors account for about 10% of the total protein in plasma. They provide one mechanism for the control of proteinase activity, thus regulating many important biological reactions such as blood coagulation. Most plasma inhibitors are specific for one or a few related proteinases and control a particular biological event or pathway. Two other inhibitors, the alpha 2-macroglobulin (alpha 2M) and the alpha 1-proteinase (alpha 1PI = alpha 1-antitrypsin) have a broader specificity. The role of alpha 1PI, although theoretically able to inhibit a large number of enzymes, is the inhibition of leukocytic elastase. This function is particularly important in the lung where elastase may be released from neutrophils particularly in smokers. alpha 2-Macroglobulin reacts with a large number of very different proteinases by a mechanism quite different from those of the other inhibitors. The physiological role of this inhibitor is not clearly understood although it may act as a "back-up" inhibitor when levels of other inhibitors are low or if no specific inhibitor is available.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208604

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  3 in total

1.  SERPINA3 induced by astroglia/microglia co-culture facilitates glioblastoma stem-like cell invasion.

Authors:  Yang Li; Xingli Dong; Jinquan Cai; Shi Yin; Ying Sun; Dongbo Yang; Chuanlu Jiang
Journal:  Oncol Lett       Date:  2017-10-26       Impact factor: 2.967

2.  Up-regulation of SERPINA3 correlates with high mortality of melanoma patients and increased migration and invasion of cancer cells.

Authors:  Jiaying Zhou; Yabin Cheng; Liren Tang; Magdalena Martinka; Sunil Kalia
Journal:  Oncotarget       Date:  2017-03-21

3.  Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells.

Authors:  Yingzi Zhang; Jiao Tian; Chi Qu; Yang Peng; Jinwei Lei; Kang Li; Beige Zong; Lu Sun; Shengchun Liu
Journal:  Breast Cancer       Date:  2021-02-10       Impact factor: 4.239

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.